ABSTRACT

The exact definition of high-risk prostate cancer remains controversial. D’Amico defined it as a PSA value >20 ng/mL, biopsy Gleason score 8-10 or clinical stage ≥T2c. High-risk prostate cancer is potentially lethal disease and accounts for 14-24% of all new diagnosis. The current role of radical prostatectomy and lymphadenectomy in patients with high-risk prostate cancer remains controversial. But, there are many substantial results that support the use of radical prostatectomy with extended pelvic lymph node dissection for patients with high-risk prostate cancer in current literature. So, radical prostatectomy and extended pelvic lymph node dissection must be represented as a primary treatment option for selected high-risk patients. This treatment can result in long-term progression-free survival.